While it is still early days for Caribou, early signs suggest it could have the first off-the-shelf program to rival established CAR-T therapies.

A turbulent 2021: we are now in our eighth year of reviewing R&D productivity and corporate growth of the top 30 biopharma companies. While 2021 was dominated by the COVID-19 pandemic, biopharma as a whole had a good but not great year.

The firm is laying off a big piece of its workforce and deprioritizing some investments to free up capital for potential upcoming launches, but that could add commercial risks.

Gene and cell-based therapeutics attracted the bulk of regenerative medicine investment last year, with gene-editing approaches garnering confidence following key clinical milestones, new research shows.